Results 51 to 60 of about 27,592 (211)

Multiparticulate Systems of Ezetimibe Micellar System and Atorvastatin Solid Dispersion Efficacy of Low-Dose Ezetimibe/Atorvastatin on High-Fat Diet-Induced Hyperlipidemia and Hepatic Steatosis in Diabetic Rats

Pharmaceutics, 2021
The aim of this study was to develop multiparticulate systems with a combination of ezetimibe micellar systems and atorvastatin solid dispersions using croscarmellose as a hydrophilic vehicle and Kolliphor RH40 as a surfactant.
Carlos Torrado-Salmerón, Víctor Guarnizo-Herrero, Joana Henriques, Raquel Seiça, Cristina M. Sena, Santiago Torrado-Santiago   +5 more
doaj   +1 more source

William H. Sorrell, Attorney General of Vermont, et al. v. IMS Health Inc., et al. - Amicus Brief in Support of Petitioners [PDF]

, 2011
On April 26, 2011, the US Supreme Court will hear oral arguments in the Vermont data mining case, Sorrell v. IMS Health Inc. Respondents claim this is the most important commercial speech case in a decade. Petitioner (the State of Vermont) argues this is
Orentlicher, David, Outterson, Kevin, Pasquale, Frank A, Robertson, Christopher T.   +3 more
core   +2 more sources

Ezetimibe promotes CYP7A1 and modulates PPARs as a compensatory mechanism in LDL receptor-deficient hamsters

Lipids in Health and Disease, 2020
Background The LDL-C lowering effect of ezetimibe has been attributed primarily to increased catabolism of LDL-C via up-regulation of LDL receptor (LDLR) and decreased cholesterol absorption.
Bin Xia, Ping Lin, Yubin Ji, Jiayu Yin, Jin Wang, Xiaoqian Yang, Ting Li, Zixun Yang, Fahui Li, Shoudong Guo   +9 more
doaj   +1 more source

Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia [PDF]

, 2016
Statin-ezetimibe combinations are a potentially advantageous therapeutic option for high-risk patients who need additional lowering of low-density lipoprotein cholesterol (LDL-C).
Ferreira, AM, Marques da Silva, P
core   +1 more source

Ezetimibe: An Unusual Suspect in Angioedema

Case Reports in Medicine, 2020
We describe a case of new onset angioedema likely due to Ezetimibe therapy in an elderly patient with a prior history of drug-induced bradykinin reactions who had been on the medication for multiple years.
Tiffany Lu, Tarundeep Grewal
doaj   +1 more source

Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial [PDF]

, 2018
BACKGROUND: The effects of ezetimibe on cholesterol metabolism in HIV-infected patients receiving boosted protease inhibitors have not been thoroughly assessed.
Cofán Pujol, Montserrat, Forga, María T., Larrousse Morellón, Maria, Leyes, Pere, Martínez Chamorro, Esteban José, Pérez-Heras, Ana Maria, Ros Rahola, Emilio, Trabal, Joan   +7 more
core   +1 more source

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source

Increased coproporphyrin serum levels in healthy volunteers treated with the cholesterol uptake inhibitor ezetimibe

Clinical and Translational Science
Ezetimibe undergoes glucuronidation that results in the active metabolite ezetimibe phenoxy‐glucuronide (ezetimibe‐glucuronide). This phase‐II metabolite was shown to interact with the clinically relevant hepatic transporter organic anion transporting ...
Jonny Kinzi, Markus Grube, Isabell Seibert, Werner Siegmund, Henriette E. Meyer zu Schwabedissen   +4 more
doaj   +1 more source

Ezetimibe in combination with a statin does not reduce all-cause mortality [PDF]

, 2013
BACKGROUND: Although the ezetimibe-statin combination has been shown to reduce LDL cholesterol by 12% compared to a statin alone, its effect on hard clinical endpoints such as mortality is less certain.
Marr, Joshua, Patel, Akshar Y, Pillarisetti, Jayasree, Vacek, James L   +3 more
core   +2 more sources

Plaque Morphology‐Dependent Regression of Tandem Coronary Plaques Under Intensive Lipid‐Lowering Therapy

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT We report a 54‐year‐old woman with stable angina who exhibited heterogeneous responses of tandem left anterior descending artery (LAD) plaques to intensive lipid‐lowering therapy. Coronary CT angiography performed at another hospital suggested diffuse disease, and she presented to our clinic for a second opinion.
Yong‐Lee Kim, Hyoun‐Woo Noh, Chang‐Ok Seo, Jeong Rang Park, KyeHwan Kim, Hye Ree Kim, Jin‐Yong Hwang, Min Gyu Kang, Hangyul Kim, Jin‐Sin Koh   +9 more
wiley   +1 more source